Trials / Completed
CompletedNCT00004688
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (planned)
- Sponsor
- Emory University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
OBJECTIVES: I. Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine, streptozocin, and mercaptopurine.
Detailed description
PROTOCOL OUTLINE: Patients receive mercaptopurine IV on days 1-3, carmustine by continuous infusion on days 3-5, and streptozocin IV over 20 minutes on days 2-5. Patients receive treatment every 42 days, for up to 4 courses. Completion date provided represents the completion date of the grant per OOPD records
Conditions
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Mixed Gliomas
- Glioblastoma Multiforme
- Recurrent Brain Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | carmustine | |
| DRUG | mercaptopurine | |
| DRUG | streptozocin |
Timeline
- Start date
- 1996-08-01
- Completion
- 1998-07-01
- First posted
- 2000-02-25
- Last updated
- 2015-03-25
Source: ClinicalTrials.gov record NCT00004688. Inclusion in this directory is not an endorsement.